

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/080959 A1

- (51) International Patent Classification⁷: **A61K 38/21**, A61P 9/10 (74) Agent: PRINS, A., W.; Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).
- (21) International Application Number: PCT/NL01/00276 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 3 April 2001 (03.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicants (*for all designated States except US*): UNIVERSITAIR MEDISCH CENTRUM UTRECHT [NL/NL]; Heidelberglaan 100, NL-3584 CX Utrecht (NL). UNIVERSITEIT UTRECHT [NL/NL]; Faculty of Medicine, Heidelberglaan 100, NL-3584 CX Utrecht (NL).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): VELDHUIS, Wouter, Bernard [NL/NL]; Laan van Soestbergen 27-bis, NL-3582 SR Utrecht (NL). VAN DER MEIDE, Petrus, Hendrikus [NL/NL]; Kastanjelaan 2, NL-2631 HT Nootdorp (NL). NICOLAY, Klaas [NL/NL]; Tournooicamp 12, NL-3992 CM Houten (NL).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/080959 A1

(54) Title: METHOD OF TREATMENT OF HYPOXIA/ISCHAEMIA BLUTFLUSSWIDERSTAND

(57) Abstract: The present invention provides means and methods for at least a partial prevention of cellular damage in disease resulting from H/I-related blood flow resistance, preferably due to occlusion of blood vessels. Administration of β -interferon before, around or after the time of lifting of the ischemia results in improved survival of cells downstream of the occluded blood vessel, presumable because micro-vasculature downstream of the lifted obstruction is prevented from clogging. Prevention of blood flow impairment presumably leads to increased survival of cells in tissue affected by the ischemia.

METHOD OF TREATMENT OF HYPOXIA/ISCHAEMIA BLUTFLUSSWIDERSTAND

The invention relates to the field of medicine. The invention more in particular relates to the treatment of diseases, more specifically diseases in which interruption of blood flow and/or activation/infiltration/proliferation of immune cells is detrimental.

5

Interruption of blood flow is detrimental to tissue and in fact is the cause of a variety of human disease. Restoration of blood flow, spontaneous and/or treatment-induced can theoretically salvage all or part of the affected tissue. The success of this reperfusion in preventing further tissue damage is
10 amongst others dependent on the severity of blood flow decrease and the time to restoration of blood flow to levels compatible with cell survival.

Treatment directed to increase blood flow - and/or spontaneous restoration of blood flow - to therapeutically relevant levels is often counteracted by a phenomenon that we refer to as hypoxia/ischaemia (H/I)
15 related flow resistance. It is very often observed that the microvasculature downstream of the site of obstruction responds by resisting the increased blood flow following removal of the obstruction. The H/I related flow resistance counteracts the quality of tissue perfusion after removal of the primary obstruction, or, when the obstruction has not (yet) been removed: the quality of
20 the remaining perfusion. This phenomenon is not only relevant in situations where blood supply is temporarily interfered with. A similar phenomenon is observed in situations where the demand for blood flow is chronically lower than the supply. Although the term hypoxia refers to situations of oxygen shortage, the phenomenon does not have to be related to the oxygen shortage.
25 The term is here only used to indicate a situation in or after which the phenomenon is observed. H/I related flow resistance is a problem in a variety of human disease. Various associations and explanations for the resistance

have been proposed, however as of yet this has not led to the development of improved therapies.

The present invention now provides a method for the treatment of
5 H/I related blood flow resistance in an individual comprising administering to
said individual a therapeutically relevant dose of interferon- β or a functional
part, derivative and/or analogue thereof. Administration of said dose leads to
reduced H/I related flow resistance in said individual. Perfusion of tissue
displaying H/I related blood flow resistance in the untreated individual, is
10 improved in the comparable tissue in the treated individual. Improved
perfusion results in less damage, better recovery or improved repair of the
affected tissue. H/I related blood flow resistance does not have to be displayed
by the individual. Prophylactic application is also beneficial. I.e. when it is
expected that H/I related blood flow resistance can occur in an individual said
15 individual can be treated with a method of the invention and profit from the
resulting improved perfusion as compared to the situation where no interferon-
 β or functional part, derivative and/or analogue thereof, is given to said
individual. As a non-limiting example this situation is illustrated for instance
in surgery where one or more parts of the body may suffer from reduced blood
20 flow due to isolation from the circulation. With the phrase "treatment of H/I
related blood flow resistance" is meant that said blood flow resistance is at
least in part reduced as a result of said treatment. Complete disappearance of
the blood flow resistance is possible but not required in the present invention.

H/I related blood flow resistance can occur in many situations. A
25 person that has not been able to breath oxygen for a limited amount of time,
for instance, because the individual is in a situation where he/she has to be
resuscitated, can be treated with a method of the invention and expect a
beneficial effect on the overall perfusion. In a preferred embodiment of the
invention said H/I related blood flow resistance is the result of a shortage in
30 blood supply. A situation where H/I related blood flow resistance can occur is

very frequently a local problem. Therefore typically, said H/I related blood flow resistance is restricted to a part of the body of said individual, preferably due to an obstruction of a blood vessel. An obstruction can be a complete obstruction of a vessel allowing no passage of blood. An obstruction can also be an incomplete obstruction of a vessel that disables the flow of blood to meet the demand of blood flow. An obstruction can be in the form of a clot that clogs the vessel. However, an obstruction can also be the closing of a vessel by force exerted from the outside for instance due to claspings. An obstruction can also be caused by a cut effectively interfering with proper blood flow.

10 In one aspect the invention therefore provides a method for the treatment of a H/I related blood flow resistance in an individual, said individual comprising at least one blood vessel obstruction causing ischaemia (the supply of blood lags behind the demand of blood, whether due to obstructions, increased demand, lowered level of oxygen and/or nutrients in
15 the blood or any other way) in tissue that is situated downstream from said obstruction, said method comprising administering to said individual a therapeutic dose of interferon- β or a functional part, derivative and/or analogue thereof. A treatment of the invention preferably results in improved survival of cells in said individual, preferably, said cells comprises neuronal
20 cells. In another aspect the invention provides a method for at least in part improving blood flow in post-ischemic tissue comprising administering to an individual, having said tissue, β -interferon or a functional part, derivative and/or analogue thereof. In yet another embodiment the invention provides a method for at least in part preventing cell death in post-ischemic tissue
25 comprising administering to an individual, having said tissue, β -interferon or a functional part, derivative and/or analogue thereof. Preferably, said cell death is in part prevented in neuronal tissue.

In a preferred aspect of the invention said H/I related blood flow resistance is restricted to the brain, the heart, a transplanted organ and/or a
30 limb. A method of the invention can be used to improve survival of

transplanted organs or parts thereof. In organ transplantation, reperfusion injury is an inflammatory cell-mediated response that causes tissue damage immediately following transplantation. This process has been implicated in the development of acute and chronic rejection of transplants. NF- κ B is a transcription factor that upregulates adhesion molecules ICAM-1, VCAM-1, and E-selectin following reperfusion. Systemic treatment with sulfasalazine, a potent inhibitor of NF- κ B, was shown to decrease adhesion molecule expression, decrease reperfusion injury, and prolong allograft survival in rat cardiac transplants. β -interferon reduces the expression of adhesion molecules, eg VCAM-1, and can be administered to an individual according to a method of the invention to prolong allograft survival.

In a preferred embodiment, said H/I related blood flow resistance is restricted to a part of the brain and/or the heart. Particularly the brain is preferred because the administration of β -interferon or a functional part, derivative and/or analogue thereof, has a dramatic effect on H/I related flow resistance in this part of the body. Administration results in significantly less neuronal damage, because blood flow in the affected area is increased significantly compared to untreated individuals. Due to this effect the volume of the damaged area in the brain as a result of the administration is significantly reduced compared to untreated. In a preferred embodiment β -interferon or a functional part, derivative and/or analogue thereof, is administered to patients in which the blood flow is insufficient in an area of the brain, preferably as the result of a stroke or trauma. In cases where an obstruction of a vessel is the reason for the insufficient blood flow it is preferred that the compound is administered as soon as possible, and preferably even before occurrence of said obstruction. Administration can even prolong the time window in for the (partial) removal of the obstruction. In this case administration is continued until a more or less stable situation has been arrived at. In cases where hypoxic/ischaemic tissue is reperfused, or perfused

to a larger extend, a stable situation typically is arrived at within one week after the increased supply of blood flow was initiated.

It is thought that in the brain, ischaemia and trauma elicit an inflammatory response in which mediators (cytokines, chemokines and adhesion molecules) are released and immune cells infiltrate the injured brain. Upregulation of pro-inflammatory cytokines, chemokines and endothelial-leukocyte adhesion molecules starts soon after focal ischemia and trauma and continues during the evolution of tissue injury. For leukocytes to gain access to their target tissues, a variety of signaling proteins and adhesion molecules act in concert to permit chemotaxis, endothelial cell attachment and transmigration. For example a rapid overproduction of TNF-alpha leads to the stimulation of adhesion molecule expression with subsequent accumulation of leukocytes in the ischemic focus. Focal adhesion of leukocytes to the endothelium is a key step in inflammation and certain vascular disease processes. P- and E-selectin and ICAM-1, expressed by activated endothelium, and the leukointegrin CD11/CD18 expressed by activated leukocytes, have been shown to be crucial to this adhesion. E-selectin and ICAM-1 are synthesized by stimulation with cytokines such as IL-1 and TNF. Immunoreactivity to ICAM-1 and CD11/CD18 has been demonstrated after 60 min transient focal ischemia in the rat, in both core and penumbra, increasing from 3 to 24h after reperfusion. Leukocytic infiltration in this example was seen in the ischemic areas from 12 to 24h after reperfusion. The postulated effects of leukocytes in the pathogenesis of cerebral ischemic damage are as follows: a reduction in cerebral blood flow by vessel plugging and/or release of vasoconstrictive mediators such as endothelin and exacerbation of BBB- or parenchymal injury via hydrolytic enzyme release, oxygen radical production and lipid peroxidation. IFN- γ stimulates IL-10 production which could in theory result in decreased TNF-alpha and IFN-gamma production. In traumatic brain injury (TBI), the dysfunction of the blood-brain barrier is mediated by intracerebral neutrophil accumulation, chemokine release (eg IL-

8) and upregulation of adhesion molecules (eg ICAM-1, VCAM-1). In patients with severe TBI, it was found that elevated cerebrospinal fluid IL-8 and soluble (s)ICAM-1 correlated with BBB-dysfunction. IL-8 and sICAM-1 were upregulated for 19 days after severe TBI, whereas their stimulator TNF-alpha
5 was upregulated for 9 days. The same holds true for critical limb ischemia. The present invention is also of use in individuals that are suffering from stroke or atherosclerosis in general. Adhesion of monocytes to the surface of intact endothelial cells appears to be an early event in the development of atherosclerotic lesions. The chemokines, monocyte chemoattractant protein-1
10 (MCP-1) and IL-8, are found in human atheroma, and mice lacking receptors for these chemokines are less susceptible to atherosclerosis and have fewer monocytes in vascular lesions. In vitro it was shown that MCP-1 and IL-8 cause monocytes to adhere to monolayers expressing E-selectin.

In the heart, coronary endothelial dysfunction after ischemia and
15 reperfusion has been demonstrated. This endothelial dysfunction could be prevented by ischemic preconditioning. Experiments performed on cultured cells showed that the endothelial protection induced by preconditioning was due to a lesser expression of endothelial adhesion molecules such as ICAM-1, leading in vivo to a lesser adhesion of neutrophils to endothelial cells.

20 The reasonings given above are given only to provide the reader with a possible mechanism. The striking effects of β -interferon or a functional part, derivative and/or analogue thereof on blood flow as demonstrated in the present invention can also be caused through an entirely different mechanism.

25 In another aspect, the invention provides a use of β -interferon or a functional part, derivative and/or analogue thereof for the preparation of a medicament for the treatment of H/I related blood flow resistance. Preferably, said blood flow resistance is correlated with ischemia.

In yet another aspect the invention provides a use of β -interferon or a functional part, derivative and/or analogue thereof for the preparation of a medicament for the treatment of impairment of blood flow recovery. Preferably, said impairment is in a capillary vessel. Preferably, said
5 impairment is in the brain. The invention further provides a use of β -interferon or a functional part, derivative and/or analogue thereof for the preparation of a medicament for at least in part preventing cell death in post-ischemic tissue.

10 The present invention also provides means and methods for at least in part preventing ischemia related damage to tissue. Reduction in tissue damage is, most likely, the result of reduced micro-vascular clogging, which occurs in situ in microvessels downstream from the site of occlusion. Reduced micro-vascular clogging prevents deterioration of blood flow in the
15 microvasculature downstream of the ischemia upon the (partial) removal of the primary occlusion. In one aspect the invention therefore provides a method for at least in part improving blood flow in tissue that has suffered or is suffering from ischemia, comprising administering to an individual, having said tissue, β -interferon or a functional part, derivative and/or analogue thereof.
20 β -Interferon or a functional part, derivative and/or analogue thereof may be administered before the cause for the ischemia is removed. Preferably, said β -interferon or a functional part, derivative and/or analogue thereof is given as soon as possible, however, together or immediately after treatment given to (partially) remove the occlusion is also possible. In a preferred
25 embodiment β -interferon or said functional part, derivative and/or analogue thereof is administered as soon as possible after the obstruction has occurred. In this way medication or other methods to remove the obstruction is given a larger time window for effect. Thus improving the chances of recovery for a patient. In some diseases caused by occlusion of blood vessels, the current
30 perception is that there is no urgency in giving treatment since there is no

effective way to prevent the tissue damage. A good example of such a disease is stroke. Very often, the fact that a patient had a stroke is not considered reason for immediate treatment the patient. Although with the advent of rtPA-treatment this is starting to change.

- 5 It is generally thought that damage inflicted by the stroke is already irreversible by the time a patient is hospitalized and available for treatment. With the present invention it will be apparent that there is a good reason for rapid treatment of patients. With the means and methods of the invention it is possible to at least in part reduce the extent of tissue damage. The invention
10 therefore further provides a method for at least in part preventing cell death in post-ischemic tissue comprising administering to an individual, having said tissue, β -interferon or a functional part, derivative and/or analogue thereof.

- β -Interferon is currently used in the chronic treatment of MS
15 patients and has been reported to cause systemic side-effects in this patient group. The systemic reaction is usually described as flu-like. Fever, chills, muscle aches, sometimes headaches, often commence a few hours after the drug is injected and last for some hours. In non-chronic cases administration of β -interferon can be discontinued after a relatively short period, often no longer
20 than 1 week after the onset of the disease.

- In the present invention the functionality of β -interferon or a functional part, derivative and/or analogue is used to at least in part prevent impairment of blood flow in post-ischemic tissue. A functional part of β -interferon is a part of β -interferon comprising the same post-ischemic damage
25 reduction activity in kind as β -interferon itself. The amount of activity of such a part may differ from the activity of the complete protein. A person skilled in the art is capable of generating a suitable derivative of β -interferon. Derivatives can be for instance be obtained by conservative amino acid substitution, indeed currently prescribed human β -IFNs differ slightly in

amino acid sequence from natural human β -IFN. A suitable part of β -interferon is for instance a part with a reduced amount of glycosylation. Glycosylation can be prevented by removing or altering a glycosylation site of the molecule. If the generation of such a (partially) deglycosylated β -interferon requires alteration of the amino acid composition than such a deglycosylated β -interferon is derivative of a functional part of β -interferon. A functional part, derivative and/or analogue of β -interferon comprises the same activity in kind not necessarily in amount.

In general, β -interferon may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype (important are for example: increased IL-10, decreased IL-2, IFN-gamma and decreased TNF-alpha), and this appears to occur in the systemic circulation and within the CNS.

For suitable doses ranges and formulations of β -interferon or a functional part, derivative and/or analogue thereof one may turn to literature regarding the use of said compound in humans in other disease area's such as multiple sclerosis. Additionally, dose finding studies can give suitable therapeutic doses for the present invention. By way of example a dose of 8M IU Betaseron, s.c., every other day; the currently accepted dosage regime for relapsing remitting MS. A 1.6 M IU dosage every other day was well tolerated by the patient. [Biomed Pharmacother. 1999 Sep;53(8):344-50. Review]. [Biomed Pharmacother. 1999 Sep;53(8):344-50. Review].

The administration of β -interferon or a functional part, derivative and/or analogue thereof, can be combined with on or more other compounds. Preferably said compound blocks the upregulation of adhesion molecules on endothelium or on the cells they would bind. However antibody against these receptors, shielding it and preventing binding or a chemokine-antagonist that

inhibits the activity of chemokines regulating adhesion molecule expression is also suitable. Also, some forms of IFN-alpha can have similar effects.

5 In a preferred embodiment β -interferon or a functional part, derivative and/or analogue thereof is combined with treatment given to remove an obstruction from a vessel. Preferably, said treatment comprises administration of rtPA or similar compound.

10 In another aspect the invention provides a use of β -interferon or a functional part, derivative and/or analogue thereof for the preparation of a medicament for the treatment of hypoxia-induced flow resistance. The invention also provides a use of β -interferon or a functional part, derivative and/or analogue thereof for the preparation of a medicament, said medicament
15 capable of at least in part preventing cell death in post-ischemic tissue. Preferably, said impairment is in micro-vessels. More preferably, wherein said impairment is in the brain.

20 Examples

Materials and Methods

Animal model

25 Male Fischer rats (F344/Ico, Iffa-Credo Broekman, Someren, The Netherlands) aged 8-12 weeks were used in all experiments. Animals had free access to standard laboratory chow and water. Anesthesia was induced by i.p. injection of a mixture of 0.5 ml/kg fentanyl citrate (0.315 mg/ml) and fluanisone (10.0 mg/ml), and 0.5 ml/kg midazolam (5.0 mg/ml), followed by s.c. injection of 0.1
30 ml/kg (0.5 mg/ml) atropine sulfate and i.p. injection of 0.5 ml/kg

gentamicinsulfate (10 mg/ml). The animals were endotracheally intubated and mechanically ventilated with O₂/N₂O (30/70 v/v). Body temperature was maintained at 37.0 ± 0.5 °C by means of a feedback-controlled heating pad. During surgery and NMR-measurements anesthesia was continued by adding
5 1-1.5% halothane to the O₂/N₂O mixture. After surgery animals received 1 ml/kg buprenorfine s.c. (0.3 mg/ml).

Transient focal ischemia was induced by unilateral tandem occlusion of the right common carotid artery (CCA) and middle cerebral artery (MCA) via a modification of the procedure as described by Brint et al. (1988). Briefly, a 2
10 mm Ø hole was drilled just rostral to the oval foramen, exposing the right middle cerebral artery (MCA). After opening the dura and arachnoidea the MCA was transiently occluded using a vascular microclip (Codman). Reperfusion was reinstated after 60 minutes under visual inspection by removing the clip.

15 Animals were treated with s.c. injections of 500.000 IU rrIFN-β in 1 ml phosphate buffered saline (PBS) once daily until 7 days after reperfusion (n=9). Control animals (n=5) received s.c injections with saline, starting 2 days prior to surgery up to 7 days after reperfusion. Treated animals were divided into three groups (n=3x3): treatment for group 1 started 2 days prior to
20 surgery, treatment for group 2 started upon reperfusion and treatment for group 3 started 3 hours after reperfusion.

NMR experiments

NMR-experiments were performed on a 4.7T Varian horizontal bore
25 spectrometer equipped with a gradient insert able to achieve gradients up to 220 mT/m in 300 μs. Rf-excitation and signal detection were accomplished by means of a Helmholtz volume coil (9 cm Ø) and an inductively coupled surface coil (2 cm Ø), respectively. Animals were positioned in an animal cradle and immobilized with ear bars. During the experiments exhaled CO₂ and rectal
30 temperature were continuously monitored.

A single-scan diffusion-trace MRI-sequence (4 b's:100-1780 s/mm², repetition time (TR)=2s, echo time (TE)=100 ms, number of transients (NT)=2) was used to generate quantified images of tissue water trace apparent diffusion coefficient (ADC). T₂-weighted images were acquired using a multi-echo
5 sequence (8 TEs: 17.5 ms + 7 x 17.5 ms, TR=2s, NT=2). Diffusion-weighted and T₂-weighted-data sets (collecting 8 1.7 mm thick slices, 3.2x3.2 cm² FOV, 128x64 matrix, zero-filled to 256x256) were acquired at 1, 7 and 21 days after reperfusion.

10 Data analysis

ADC and T₂ maps were generated by mono-exponential fitting using IDL (Research Systems, Boulder, USA). Parametric images were analysed in anatomic regions of interest using in-house software. Calculations of volumes of affected tissue were based on ipsilateral ADC or T₂ differing more than 20%
15 (corresponding to >2x SD) from the mean value in the contralateral hemisphere.

Statistical analysis was carried out using a linear mixed effects model (in S-PLUS 2000 Professional Edition Release 3, Mathsoft Inc., USA), with Rat as random effect and Day (the days the animals were scanned: 1, 7 and 21) and
20 Treatment (control, beta-interferon-2 days prior, beta-interferon-upon reperfusion and beta-interferon-3 hours after reperfusion) as fixed effects. Different variances per Treatment were included in the model. No interaction between Day and Treatment was found; no main Day effect either. Treatment effect was extremely significant, due to difference between control and other
25 treatments. No differences between other treatments were found.

Since there was no Day effect it was removed from further analyses. These were done using SPSS using two-tailed Student's t-tests or one-way ANOVA where appropriate.

Results

General Condition

After surgery, body weight of all animals showed an initial decrease in the
5 first postoperative days, whereafter it increased.

In two treated animals a necrotic patch, about 7.5 mm in diameter, developed
in the skin around the site of ifn-injection. The lesion was not painful to the
touch and did not hinder the animals in feeding or other behavior. For the
remaining days injection was continued at a different site, where, in these two
10 animals, necrosis did not occur.

Magnetic Resonance Imaging

ADC images acquired at 1 day after reperfusion showed cytotoxic cell swelling,
as evidenced by decreased ADC-values. In control animals both the cortex and
15 a large part of the caudateputamen of the ipsilateral hemisphere were
affected, while in interferon-treated animals a smaller part of the
caudateputamen and no part or a only small rim of cortex showed cytotoxic
cell swelling (see fig. 1). At this timepoint the volume of the lesion on ADC
maps (ALV) was 76% smaller ($p < 0.0005$) in treated animals compared to
20 controls (see figs. 3 and 4). Also, in interferon-treated animals the severity of
tissue damage, as determined from the severity of ADC-reduction, was 15%
less ($p < 0.002$) than in control animals (see fig. 5). There was no significant
difference between the three treatment groups in terms of the T_2 data.

T_2 maps acquired at day 1 showed the development of vasogenic edema in the
25 affected tissue, the volume of which was 64% smaller ($p < 0.021$) in treated
animals compared to controls (see figs. 2, 7 and 8). This difference is also
demonstrated by the midline-shift caused by swelling of the brain tissue,
which is absent or much less pronounced in treated animals compared to
controls (see fig. 2). There was no significant difference between the three
30 treatment groups.

ADC data acquired during the endpoint measurement on day 21 showed ADC values had increased to supranormal values, indicative of vasogenic edema and tissue loss (see figs 1, 3 and 4). At this timepoint the infarct as present on ADC maps was reduced by 82% ($p < 0.0005$) in treated animals compared to
5 controls.

T_2 map data acquired on day 21 confirmed the presence of vasogenic edema and tissue loss (see figs 2, 7 and 8). Infarct size as determined from T_2 maps was 89% smaller ($p < 0.0005$) in interferon treated animals compared to controls.

10 To summarize, treatment with interferon- α affords important neuroprotection to ischemic brain. Already at 1 day after reperfusion, the amount of tissue at risk to undergo permanent infarction identified by the ADC data, is significantly smaller in interferon-treated animals than in control animals. Permanent damage as assessed by T_2 MRI shows the protection afforded at
15 day 1 extends until at least 3 weeks after the insult, at which timepoint the volume of infarcted tissue is 89% smaller in treated animals compared to controls.

There was no significant difference between starting treatment 2 days prior to
20 the insult, starting upon reperfusion or starting 3 hours after reperfusion, the latest timepoint tested, indicating a treatment window of 4 hours after onset of stroke and possibly longer.

Legends to the figures

Fig 1. ADC maps of a slice through the center of the lesion acquired on day 1, 7 and 21.

- 5 Top row: Animal treated with s.c. injections of saline.
 Bottom row: Animal treated with s.c. injections of 500.000 IU rrIFN- β , starting at 3h after reperfusion.

Fig 2. T₂ maps of a slice through the center of the lesion acquired on day 1, 7 and 21.

- 10 Top row: Animal treated with s.c. injections of saline.
 Bottom row: Animal treated with s.c. injections of 500.000 IU rrIFN- β , starting at 3h after reperfusion.

- 15 **Fig 3. Lesion volume of the control group and all treatment groups, on days 1, 7 and 21 as calculated from ADC maps.**

Fig 4. Lesion volume of the control group versus all treatment groups together, on days 1, 7 and 21 as calculated from ADC maps.

- 20 **Fig 5. Mean lesion ADC value of the control group and all treatment groups, on day 1 as calculated from ADC maps. All values were decreased compared to normal tissue (0.00073 mm²/s); control animals showed a stronger decrease in lesion ADC value.**

- 25 **Fig 6. Mean lesion ADC value of the control group and all treatment groups, on days 7 and 21 as calculated from ADC maps. All values were increased compared to normal tissue (0.00073 mm²/s); control animals showed a stronger increase in lesion ADC value.**

- 30 **Fig 7. Lesion volume of the control group and all treatment groups, on days 1, 7 and 21 as calculated from T₂ maps.**

- 35 **Fig 8. Lesion volume of the control group versus all treatment groups together, on days 1, 7 and 21 as calculated from T₂ maps.**

- 40 **Fig 9. Mean lesion T₂ value of the control group and all treatment groups, on days 1, 7 and 21 as calculated from T₂ maps. All values were increased compared to normal tissue (0.055 s); control animals showed a stronger increase in lesion T₂ value.**

Fig 10. Mean lesion T₂ value of the control group versus all treatment groups together, on days 1, 7 and 21 as calculated from T₂ maps. All

values were increased compared to normal tissue (0.055 s); control animals showed a stronger increase in lesion T_2 value.

References

- Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W (1988) Focal brain ischemia in the rat: methods for reproducible neocortical infarction using
5 tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. *J Cereb Blood Flow Metab* 8:474-485.
- Biomed Pharmacother. 1999 Sep;53(8):344-50. Review
- Biomed Pharmacother. 1999 Sep;53(8):344-50. Review

Claims

1. A method for the treatment of a hypoxia/ ischaemia (H/I) related blood flow resistance in an individual comprising administering to said individual a
5 therapeutically relevant dose of interferon- β or a functional part, derivative and/or analogue thereof.
2. A method according to claim 1, wherein said H/I related blood flow resistance is the result of a shortage in blood supply.
3. A method according to claim 1 or claim 2, wherein said H/I related blood
10 flow resistance is restricted to a part of the body of said individual.
4. A method according to claim 3, wherein said part, comprises the brain, the heart, a transplanted organ and/or a limb.
5. A method according to claim 4, wherein said hypoxia related blood flow resistance is restricted to a part of the brain and/or the heart.
- 15 6. A method according to any one of claims 1-5, wherein said H/I related blood flow resistance is induced by an obstruction in an artery.
7. A method for the treatment of a H/I related blood flow resistance in an individual, said individual comprising at least one blood vessel obstruction causing ischaemia in tissue that is situated downstream from said
20 obstruction, said method comprising administering to said individual a therapeutic dose of interferon- β or a functional part, derivative and/or analogue thereof.
8. A method for at least in part improving blood flow in post-ischemic tissue comprising administering to an individual, having said tissue, β -interferon
25 or a functional part, derivative and/or analogue thereof.
9. A method for at least in part preventing cell death in post-ischemic tissue comprising administering to an individual, having said tissue, β -interferon or a functional part, derivative and/or analogue thereof.

10. Use of β -interferon or a functional part, derivative and/or analogue thereof,
for the preparation of a medicament for the treatment of hypoxia-related
blood flow resistance.
11. Use according to claim 10, wherein said blood flow resistance is correlated
5 with ischemia.
12. Use of β -interferon or a functional part, derivative and/or analogue thereof
for the preparation of a medicament for the treatment of impairment of
blood flow recovery.
13. Use of β -interferon or a functional part, derivative and/or analogue thereof
10 for the preparation of a medicament for at least in part preventing cell
death in post-ischemic tissue.
14. Use according to any one of claims 10-13, wherein said impairment is in a
capillary vessel.
15. Use according to any one of claims 10-14, wherein said impairment is in
15 the brain.

Fig. 1






Fig. 2




3/10

Fig. 3



4/10






Fig. 5




Fig. 6

7/10






Fig. 8




9/10



10/10

Fig. 10



INTERNATIONAL SEARCH REPORT

PCT/NL 01/00276

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/21 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, MEDLINE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 797 998 A (TORAY INDUSTRIES) 1 October 1997 (1997-10-01) column 5, line 33-40 column 6, line 10,11 claims 4,8	1-15
X	PATENT ABSTRACTS OF JAPAN vol. 1997, no. 10, 31 October 1997 (1997-10-31) & JP 09 151137 A (TORAY IND INC), 10 June 1997 (1997-06-10) abstract	1-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

29 November 2001

Date of mailing of the international search report

06/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

INTERNATIONAL SEARCH REPORT

PCT/NL 01/00276

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0797998	A	01-10-1997	EP	0797998 A1	01-10-1997
			CA	2210622 A1	29-05-1997
			WO	9718831 A1	29-05-1997
<hr/>					
JP 09151137	A	10-06-1997	NONE		
<hr/>					

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.